Stryker sees FY25 adjusted EPS $13.45-$13.70, consensus $13.47

Sees FY25 revenue up 8%-9%. The company said, “Based on our momentum exiting 2024, a sustained level of procedural volumes, strong demand for our capital products and our presence in healthy end markets, we expect organic net sales growth to be in the range of 8.0% to 9.0% for 2025 and expect adjusted net earnings per diluted share to be in the range of $13.45 to $13.70. Our guidance reflects our expectation that the full year impact of price on sales will be modestly favorable and that if foreign exchange rates hold near current levels, full year net sales will be unfavorably impacted by approximately 1% and adjusted net earnings per diluted share will be negatively impacted by approximately $0.10 to $0.15. As it relates to the pending acquisition of Inari, we anticipate closing this transaction toward the end of February. Based on that timing, Inari is expected to deliver approximately $590 million of sales in the 2025 stub period on a constant currency basis and have dilutive impacts on adjusted operating income margin of 0 to 20 basis points and $0.20 to $0.30 on adjusted net earnings per diluted share. As it relates to the sale of our Spinal Implants business, we expect that the impact of this transaction will be absorbed in the above guidance for organic net sales growth and adjusted net earnings per diluted share.”